CN115088833A - A functional food for preventing and/or treating intestinal damage in tumor patients - Google Patents

Abstract

The invention discloses a functional food for preventing and/or treating intestinal injury of a tumor patient. The functional food contains, per 100 g: 8-9g of whey protein powder, 5-7g of soybean protein isolate, 6-8g of rapeseed oil powder, 4-7g of coconut oil powder, 20-25g of fructo-oligosaccharide, 25-30g of maltodextrin, 25-28g of resistant dextrin, 0.15-0.4 g of inulin, 0.1-0.3g of potassium gluconate, 60.004-0.006 g of vitamin B, 3100-115 IU of vitamin D, 10.0025-0.004 g of vitamin B, 0.002-0.0035g of zinc citrate, 0.0028-0.004g of manganese citrate, 0.002-0.005g of sodium chloride, 0.3-0.5g of corn flour and 5-8g of ginsenoside. The functional formula food prepared by the invention is used for preventing and/or treating intestinal injury of tumor patients through a series of experimental researches, and the results show that the functional formula food obviously improves the appetite of the patients, promotes the intake of nutrient components of the patients, has obvious protection effect on the intestinal function, and provides a new idea for the medicine research of the tumor patients.

Description

A functional food for preventing and/or treating intestinal damage in tumor patients

technical field

The invention belongs to the technical field of functional formula foods, and in particular relates to a functional food for preventing and/or treating intestinal damage in tumor patients.

Background technique

Common states of nutritional-metabolic imbalance in patients with malignant tumors include severe insufficiency of calorie intake, insufficient protein intake and a substantial increase in demand leading to muscle atrophy, increased demand for tissue repair, and the occurrence of intestinal flora characterized by significant changes in flora diversity. Dysbiosis, micronutrient deficiency and electrolyte imbalance, the body is in a hypercoagulable state. Tumor food is used in adjuvant treatment of tumor patients with intestinal flora imbalance, adverse clinical manifestations of nutrient deficiency, cancer cachexia, hyperglycemia, insulin resistance, hyperlipidemia and other tumor metabolic syndromes, hypercoagulable state, radiation enteritis, and adjuvant therapy. It plays a role in maintaining and repairing intestinal dysfunction.

Malnutrition, especially for chronically ill tumors, is the source of disease progression, slow recovery, and patient suffering. In order to meet the special needs of cancer patients for nutrients or diets with restricted eating, metabolic disorders, and digestive and absorption disorders, formula foods prepared and processed can be used to correct subsequent adverse reactions caused by cancerous malnutrition. In addition, the conventional chemotherapy drug 5-FU of tumors will be converted into 5-fluorouracil deoxynucleotide (5F-dUMP) in the cell during the treatment process, which inhibits deoxythymidylate synthase and prevents deoxyuridylic acid (dUMP) methylation. The methylation is converted to deoxythymidylate (dTMP), which affects DNA synthesis. And literature statistics show that about 50%-80% of patients will suffer from intestinal inflammation and other diseases during treatment, accompanied by gastrointestinal reactions, which are manifested as loss of appetite, nausea, vomiting, stomatitis, gastritis. , diarrhea, and even bloody diarrhea in severe cases. Therefore, it is necessary to pay close attention to the nutritional status of patients, conduct nutritional status evaluation and screening on time, and select the degree of nutritional therapy and adjuvant administration according to the disease stage of tumor patients and the different locations of the tumor. The status of nutritional therapy is equivalent to anti-tumor therapy such as surgery, radiotherapy, and drug therapy. Focusing on nutritional metabolism therapy is to relieve patients' pain, save costs, and improve the quality of life. At present, the nutritional content of nutritional preparations for gastrointestinal diseases such as intestinal inflammation in tumor patients is still relatively single and the types are relatively rare.

SUMMARY OF THE INVENTION

The purpose of the present invention is to provide a functional food for preventing and/or treating intestinal damage in tumor patients.

In order to achieve the above object, the present invention adopts the following technical solutions:

A functional food, each 100g contains: whey protein powder 8-9g, soybean protein isolate 5-7g, rapeseed oil powder 6-8g, coconut oil powder 4-7g, fructooligosaccharide 20-25g, malt paste Essence 25-30g, Resistant Dextrin 25-28g, Inulin 0.15g-0.4g, Potassium Gluconate 0.1-0.3g, Vitamin B6 0.004-0.006g, Vitamin D3 100-115IU, Vitamin B1 0.0025-0.004g, Lemon Zinc acid 0.002-0.0035g, manganese citrate 0.0028-0.004g, sodium chloride 0.002-0.005g, corn flour 0.3-0.5g, ginsenoside 5-8g.

The application of the above functional food in the preparation of a product for preventing and/or treating intestinal damage in tumor patients.

In the present invention, functional formula food is applied to the preparation of food preparations for preventing and/or treating intestinal damage of tumor patients. Therefore, it provides a new source for the preparation of food preparations for preventing and/or treating intestinal damage in tumor patients, and also discovers the new medicinal value of this functional formula food.

Description of drawings

Figure 1 shows the statistical results of tumor volume of mice in each group 15 days after administration.

Figure 2 is a photograph of the tumor volume of mice in each group 15 days after administration.

Detailed ways

The present invention will be further described in detail below with reference to the accompanying drawings and specific embodiments, but should not be construed as a limitation of the present invention. Modifications or substitutions made to the methods, steps or conditions of the present invention without departing from the spirit and essence of the present invention all belong to the scope of the present invention. In the examples, the experimental methods without specifying the specific conditions and the reagents without specifying the formula are all in accordance with the conventional conditions in the art.

Example 1

1. Reagents and animals:

Functional formula food: per 100g formula food (amino acid type, short peptide type protein, accounting for 10-15%; long-chain triglyceride LCT, medium-chain triglyceride MCT The fat part constitutes 10-16% ;Carbohydrates mainly include dextrin and certain ingredients of food starch, accounting for 70-73%, at the same time adding a variety of vitamins, minerals and trace elements necessary for the human body; Ginsenosides are extracted from ginseng drugs, accounting for 5 -8%): Whey Protein Powder 8.5g, Soy Protein Isolate 6g, Rapeseed Oil Powder 7g, Coconut Oil Powder 6g, Oligofructose 22g, Maltodextrin 25g, Resistant Dextrin 25g, Inulin 0.3g, Potassium gluconate 0.2g, vitamin B6 0.005g, vitamin D3 110IU, vitamin B1 0.003g, zinc citrate 0.003g, manganese citrate 0.003g, sodium chloride 0.004g, corn flour 0.4g, ginsenoside 6g.

Experimental animals: Adult male C57BL/6 mice, 8-10 weeks old, weighing 25-30 g, were purchased in Shanghai Experimental Animal Center, SPF animals were raised in Nantong University Experimental Animal Center, and the temperature in the laboratory animal room was 20-26 °C (Daily temperature difference≤4℃), humidity 40%～70%, lighting 12h: 12h alternating light and dark.

2. Experiment content:

Animal groups: tumor model group (A), tumor model + 5-FU group (B), tumor model + 5-FU + functional formula group (C), tumor model + 5-FU + Yibukang positive control group (D). After tumor intervention, the mice were divided into 4 groups with 6 mice in each group, and were randomly assigned according to the group.

The grouping design is shown in Table 1.

Table 1

3. Test method:

The operation is as follows:

(1) The method for establishing a mouse tumor model is as follows: take CT26.WT cells in logarithmic growth phase to prepare a single cell suspension, the cell density is 1×10 ¹⁰ cells/L, and extract 0.1 mL, that is, the number of inoculated cells is 1× 10 ⁶ were inoculated into the right armpit of inbred BALB/c mice. After 10 days, a solid tumor with a diameter of about 1 cm grew. To establish the mouse CT26.WT colon cancer orthotopic transplantation tumor model: firstly, the subcutaneous tumor-bearing mice were sacrificed, the skin was disinfected, the subcutaneous tumor was peeled off, and the subcutaneous tumor was immediately immersed in 100 U/mL normal saline containing penicillin and streptomycin, and the surrounding connective tissue was removed. , Take the fish-like tissue with vigorous tumor growth and cut it into pieces of 1mm ³ size for use. The C57BL/6 mice were weighed and anaesthetized by intraperitoneal injection of 2% sodium pentobarbital 100 mg/kg on the right side. The left lower abdominal incision was made about 1 cm, and the skin and subcutaneous layer on the right side of the incision were slightly dissociated to expose the cecum, drag it out to the subcutaneous, and close the abdominal cavity at the upper and lower edges of the incision. Use a 4-gauge needle to gently scrape off a little serosa at the junction of the cecum and colon, if there is blood exudation, select 1 prepared tumor mass and stick it to the incision, glue it with Histoacryl medical tissue glue, and put the external intestinal segment back in. Abdominal, suture the abdominal wall. The whole process follows the principle of aseptic operation. After awake, the mice were placed in a SPF animal room and reared routinely.

(2) Select the mice with successful modeling and randomly divide them into four groups, with 6 mice in each group, divided into tumor model group, tumor model + 5-FU group, tumor model + 5-FU + functional formula group, tumor model +5-FU + Yibukang positive control group. The three groups were intraperitoneally injected with fluorouracil solution (30 mg·kg ^-1 ) every two days, and the tumor model group was given an equal volume of normal saline by gavage every day during the experiment, and this operation was continued for 15 days.

(3) The drug was administered on the second day after the successful modeling. The tumor model + 5-FU + functional formula group and the tumor model + 5-FU + Yibukang positive control group were given the same dose of functional formula food and Yibukang according to the same calories. Nutritional preparations, the other two groups were given the same calorie feed.

4. Observation Metrics

General state observation: observation time and frequency: observed once a day at a fixed time before and after administration; observation results: the overall state of the test animals during the administration period.

After 4 weeks of treatment, the changes in the morphology and tumor volume of the mice were observed, and the changes in plasma nutritional indexes, inflammatory indexes, immune indexes, nitrogen balance, blood cell counts, and plasma proteins were detected.

(1) Changes of mouse morphology and tumor volume

The appearance of the mice, including coat color, food and water intake, mental state and activity, were observed every day. At the same time, the body weight of the mice was recorded every 7 days; the size of the tumor was measured every 3 days, and the tumor was calculated.

volume.

Tumor volume (mm)=length (mm)×width (mm)×height (mm)/2.

The next day after the administration, the mice were sacrificed by cervical dislocation, and the tumor mass was removed and weighed for recording.

(2) Nutritional indicators

After 1, 2, 3, and 4 weeks of fasting for 12 hours after successful modeling, blood was collected from the heart, anticoagulated by adding 1% disodium EDTA solution, centrifuged at 3000 r/min for 5 min, and the supernatant was taken with an automatic biochemical analyzer. Plasma total protein (Total Protein, TP) and albumin (Albumin, Alb) concentrations were determined.

(3) Inflammatory indicators

After 1, 2, 3, and 4 weeks of fasting for 12 hours after successful modeling, blood was collected from the heart, anticoagulated by adding 1% disodium EDTA solution, centrifuged at 3000 r/min for 5 min, and the supernatant was taken for ELISA.

The kits were used to measure the levels of tumor necrosis factor (Tumor Necrosis Factor, TNF-α) and interleukin-2 (Interleukin-2, IL-2) in mice.

(4) Immune indicators

After 1, 2, 3, and 4 weeks of fasting for 12 hours after successful modeling, blood was collected from the heart, anticoagulated by adding 1% disodium EDTA solution, centrifuged at 3000 r/min for 5 min, and the supernatant was taken for ELISA.

The kit measures the levels of IgG, IgA and IgM in mice.

5. Statistical analysis

The test data were expressed as Mean±SD, and the differences between groups were compared by one-way ANOVA test (M-W method). Statistical analysis results *P<0.05 considered significant difference, **P<0.01 and ***P<0.001 considered extremely significant difference.

6. Experimental results:

As shown in Figures 1 and 2, after 15 days of administration, compared with the tumor model group, the tumor model+5-FU group (###P<0.001), the tumor model+5-FU+functional formula group (###P<0.001). ##P<0.0001), tumor model + 5-FU + Yibukang positive control group (###P<0.001), the above data shows that the tumor volume of the groups receiving drug treatment was significantly reduced. At the same time, the tumor model + 5-FU + functional formula group was compared with the tumor model + 5-FU group (**P<0.01) and the tumor model + 5-FU + Yibukang positive control group (*P<0.05). , the functional formula of the present invention can effectively reduce the tumor volume, and its effect is significantly better than that of the Yibukang nutritional preparation.

The present invention prepares functional formula food for preventing and/or a series of experimental studies on the intestinal injury of tumor patients, the results show that functional formula food functional formula food significantly improves the patient's appetite, promotes the intake of nutrients in the patient, and has a good effect on the intestinal tract. The tract function has obvious protective effect, which provides a new idea for the drug research of tumor patients.

Claims (2)

1. A functional food characterized by: each 100g contains: 8-9g of whey protein powder, 5-7g of soybean protein isolate, 6-8g of rapeseed oil powder, 4-7g of coconut oil powder, 20-25g of fructo-oligosaccharide, 25-30g of maltodextrin, 25-28g of resistant dextrin, 0.15-0.4 g of inulin, 0.1-0.3g of potassium gluconate, 60.004-0.006 g of vitamin B, 3100-115 IU of vitamin D, 10.0025-0.004 g of vitamin B, 0.002-0.0035g of zinc citrate, 0.0028-0.004g of manganese citrate, 0.002-0.005g of sodium chloride, 0.3-0.5g of corn flour and 5-8g of ginsenoside.

2. Use of the functional food according to claim 1 for the preparation of a product for the prevention and/or treatment of intestinal lesions in patients with tumors.

Images